Spontaneous regression of neoplasms: new possibilities for immunotherapy

被引:25
作者
Bodey, B
机构
[1] Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90089 USA
[2] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA
关键词
angiogenesis; antineoplastic immunotherapy; carcinogenesis; cellular immunophenotype; dedifferentiation; growth factors; hormonal spontaneous regression; IL-2; metastasis; mAb; neoplastic cell redifferentiation; neoplastic cell transformation; neoplastic progression; oncogenes; tumour suppressor gene;
D O I
10.1517/14712598.2.5.459
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
in mammalian cells, neoplastic transformation is directly associated with the expression of oncogenes, loss or simple inactivation of the function of tumour suppressor genes and the production of certain growth factors. Genes for suppression of the development of the neoplastic cellular immunophenotype, as well as inhibitory growth factors, have regulatory functions within the normal processes of cell division and differentiation. Telomerase (a ribonucleoprotein polymerase) activation is frequently detected in various neoplasms. Telomerase activation is regarded as essential for cell immortalisation and its inhibition may result in spontaneous regression of neoplasms. This phenomenon of neoplasms occurs when the malignant tissue mass partially or completely disappears without any treatment or as a result of a therapy considered inadequate to influence systemic neoplastic growth. This definition makes it clear that the term,spontaneous regression' applies to neoplasms in which the overall malignant disease is not necessarily cured and to cases where the regression may not be complete or permanent. A number of possible mechanisms of spontaneous regression are reviewed, with the understanding that no single mechanism can completely account for this phenomenon. The application of the newest immunological, molecular biological and genetic insights for more individualised and adequate antineoplastic immunotherapy (alternative biotherapy) is also discussed.
引用
收藏
页码:459 / 476
页数:18
相关论文
共 231 条
[1]  
AbdelWahab Z, 1997, CANCER, V80, P401, DOI 10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO
[2]  
2-U
[3]   In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction [J].
Abe, J ;
Wakimoto, H ;
Tsunoda, R ;
Okabe, S ;
Yoshida, Y ;
Aoyagi, M ;
Hirakawa, K ;
Hamada, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 218 (01) :164-170
[4]  
ALEXANDROW MG, 1995, CANCER RES, V55, P1452
[5]  
[Anonymous], 2000, HUM GENE THER, V11, P919
[6]  
[Anonymous], TERATOMAS DIFFERENTI
[7]   Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells [J].
Arienti, F ;
SuleSuso, J ;
Belli, F ;
Mascheroni, L ;
Rivoltini, L ;
Melani, C ;
Maio, M ;
Cascinelli, N ;
Colombo, MP ;
Parmiani, G .
HUMAN GENE THERAPY, 1996, 7 (16) :1955-1963
[8]  
Aruga E, 1997, CANCER GENE THER, V4, P157
[9]   REGULATION AND PATTERNS OF ENDOGENOUS AND EXOGENOUS GENE-EXPRESSION DURING DIFFERENTIATION OF EMBRYONAL CARCINOMA-CELLS [J].
ASTIGIANO, S ;
SHERMAN, MI ;
ABARZUA, P .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1989, 80 :25-38
[10]   BIOLOGIC CONTROL OF CANCER - THE EWING,JAMES LECTURE [J].
BAKER, HW .
ARCHIVES OF SURGERY, 1986, 121 (11) :1237-1241